A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » IAS 2011

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 18, 2011

Traditional Risk Factors Greatest Risk for Bone Fractures

by Tim Horn

Though there has been a significant increase in osteoporotic bone fracture rates in the years since combination antiretroviral (ARV) therapy became commonplace in countries like the United States, the drugs themselves do not appear to be chief culprits, according to new Veterans Administration data presented Monday, July 18, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

While the study concludes that tenofovir (found in Viread, Truvada and Atripla), as well as Kaletra (lopinavir/ritonavir), were independently associated with an increased risk of osteoporotic fractures among those who started HIV treatment since 1996, the researchers point out that traditional factors for fractures—race, aging, smoking and diabetes—are much greater contributors to the risk.

As their name implies, osteoporotic fractures (OFs) involve bone that are more prone to break or fracture because they lack healthy bone mineral density levels. Areas most commonly affected include the hip, wrist and spine. OFs are sometimes referred to as fragility fractures, and they often result from a fall at standing height. And because fragility fractures can significantly reduce mobility, they can lead to other health complications and even reduce survival rates.

As Roger Bedimo, MD, of the University of Texas Southwestern Medical Center in Dallas explained in his introduction, OFs are becoming increasingly common in people living with HIV and taking ARV therapy, compared with those who are HIV negative. Though at least two studies have suggested that one commonly used ARV, tenofovir, reduces bone mineral density (BMD) more than similar HIV drugs, the risk of fractures and its association with tenofovir treatment have never been explored.

To shed light on a possible link between the two, Bedimo and his colleagues conducted an analysis of more than 56,000 people living with HIV and receiving care from the Veterans Administration between 1988 and 2009. The researchers also looked specifically at more than 33,000 veterans who starting receiving HIV care from 1996 onward—the era of combination ARV treatment. 

A total of 951 OFs were documented in the whole study population; 572 OFs were noted in those who entered care from 1996 to 2009.

About 1.61 fractures per 100 person-years were documented from 1998 to 1995, whereas the rate nearly quadrupled from 1996 to 2009.

When Bedimo’s group looked at the factors associated with OFs, white race, older age, smoking, lower body mass index and hepatitis C virus (HCV) coinfection were all considered to be statistically significant risk factors. Being on ARV therapy also was found to be a factor—there was a 5 percent increase in the risk—but when the data were adjusted to more traditional risk factors such as those listed previously, ARV treatment was not found to be independently associated with a greater risk of fragility fractures.

In looking at the entire cohort, researchers found that tenofovir and a Norvir-boosted treatment of protease inhibitors increased the risk of OFs by 8 percent and 6 percent, respectively, compared with other ARVs. However, when the data were adjusted for other risk factors, the increased risks were not statistically significant.

When Bedimo’s group looked only at those who entered HIV care and started treatment between 1996 and 2009, tenofovir was associated with an increased OF risk of 12 percent, a finding that was statistically significant after adjusting the data for other risk factors.

Norvir-boosted protease inhibitors increased the risk of OFs 8 percent. Kaletra stood out as the most likely contributor, after Bedimo’s group found that boosted Reyataz (atazanavir) and Crixivan (indinavir) were not associated with an increased risk.

While they documented links between tenofovir, Kaletra and OF risk, Bedimo and his colleagues reiterated that traditional risk factors were much greater in their associations with fragility fractures. White race, increasing age, tobacco use, diabetes, low body mass indexes (below 20) and HCV coinfection were each associated with a 10 percent or greater increase in the risk of a fragility fracture—and these factors are likely the greatest causes for concern regarding bone fractures in the modern-day HIV treatment era.

Search: bone, fracture, fragility, osteoporosis, bone mineral density, BMD, tenofovir, protease inhibitors, Kaletra, IAS, Rome, Bedimo


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dlw8585
    Fort Lauderdale
    Florida


    Loveladyd
    Washington
    DC


    ernienyc
    Bronx
    New York


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.